Cargando…
A phase 1b randomized clinical trial of CT1812 to measure Aβ oligomer displacement in Alzheimer’s disease using an indwelling CSF catheter
Autores principales: | LaBarbera, Kelsie M., Sheline, Yvette I., Izzo, Nicholas J., Yuede, Carla M., Waybright, Lora, Yurko, Raymond, Edwards, Hannah M., Gardiner, Woodrow D., Blennow, Kaj, Zetterberg, Henrik, Börjesson-Hanson, Anne, Morgan, Roger, Davis, Charles S., Guttendorf, Robert J., Schneider, Lon S., DeKosky, Steven, LeVine, Harry, Grundman, Michael, Caggiano, Anthony O., Cirrito, John R., Catalano, Susan M., Hamby, Mary E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10176668/ https://www.ncbi.nlm.nih.gov/pubmed/37173791 http://dx.doi.org/10.1186/s40035-023-00358-w |
Ejemplares similares
-
Preclinical and clinical biomarker studies of CT1812: A novel approach to Alzheimer's disease modification
por: Izzo, Nicholas J., et al.
Publicado: (2021) -
A phase 1 clinical trial of the sigma-2 receptor complex allosteric antagonist CT1812, a novel therapeutic candidate for Alzheimer's disease
por: Grundman, Michael, et al.
Publicado: (2019) -
The clinical promise of biomarkers of synapse damage or loss in Alzheimer’s disease
por: Colom-Cadena, Martí, et al.
Publicado: (2020) -
Modeling the mature CNS: A predictive screening platform for neurodegenerative disease drug discovery
por: LaBarbera, Kelsie Mozzoni, et al.
Publicado: (2021) -
Effect of escitalopram on Aβ levels and plaque load in an
Alzheimer mouse model
por: Cirrito, John R., et al.
Publicado: (2020)